halofuginone has been researched along with Pheochromocytoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dafni, H; Gross, DJ; Nagler, A; Neeman, M; Pines, M; Reibstein, I; Slavin, S; Weiss, L | 1 |
1 other study(ies) available for halofuginone and Pheochromocytoma
Article | Year |
---|---|
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Topics: Animals; Antineoplastic Agents; Cell Division; Collagen; Collagen Type I; Disease Progression; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pheochromocytoma; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Temperature; Time Factors; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2003 |